C4 Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.22
- Today's High:
- $2.34
- Open Price:
- $2.32
- 52W Low:
- $2.85
- 52W High:
- $13.235
- Prev. Close:
- $2.37
- Volume:
- 434411
Company Statistics
- Market Cap.:
- $167.80 million
- Book Value:
- 5.351
- Revenue TTM:
- $27.20 million
- Operating Margin TTM:
- -494.07%
- Gross Profit TTM:
- $-86745000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -18.43%
- Return on Equity TTM:
- -41.89%
Company Profile
C4 Therapeutics Inc had its IPO on 2020-10-02 under the ticker symbol CCCC.
The company operates in the Healthcare sector and Biotechnology industry. C4 Therapeutics Inc has a staff strength of 146 employees.
Stock update
Shares of C4 Therapeutics Inc opened at $2.32 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.22 - $2.34, and closed at $2.26.
This is a -4.64% slip from the previous day's closing price.
A total volume of 434,411 shares were traded at the close of the day’s session.
In the last one week, shares of C4 Therapeutics Inc have slipped by -21.53%.
C4 Therapeutics Inc's Key Ratios
C4 Therapeutics Inc has a market cap of $167.80 million, indicating a price to book ratio of 1.2079 and a price to sales ratio of 8.146.
In the last 12-months C4 Therapeutics Inc’s revenue was $27.20 million with a gross profit of $-86745000 and an EBITDA of $-132477000. The EBITDA ratio measures C4 Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, C4 Therapeutics Inc’s operating margin was -494.07% while its return on assets stood at -18.43% with a return of equity of -41.89%.
In Q1, C4 Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 50.9%.
C4 Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.68 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into C4 Therapeutics Inc’s profitability.
C4 Therapeutics Inc stock is trading at a EV to sales ratio of 3.2847 and a EV to EBITDA ratio of -1.5407. Its price to sales ratio in the trailing 12-months stood at 8.146.
C4 Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $396.04 million
- Total Liabilities
- $39.38 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $589000
- Dividend Payout Ratio
- 0%
C4 Therapeutics Inc ended 2024 with $396.04 million in total assets and $0 in total liabilities. Its intangible assets were valued at $396.04 million while shareholder equity stood at $262.47 million.
C4 Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $39.38 million in other current liabilities, 5000.00 in common stock, $-430670000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $49.48 million and cash and short-term investments were $305.03 million. The company’s total short-term debt was $7,114,000 while long-term debt stood at $8.62 million.
C4 Therapeutics Inc’s total current assets stands at $278.45 million while long-term investments were $34.71 million and short-term investments were $220.85 million. Its net receivables were $528000.00 compared to accounts payable of $1.03 million and inventory worth $0.
In 2024, C4 Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $589000.
Comparatively, C4 Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.26
- 52-Week High
- $13.235
- 52-Week Low
- $2.85
- Analyst Target Price
- $20.91
C4 Therapeutics Inc stock is currently trading at $2.26 per share. It touched a 52-week high of $13.235 and a 52-week low of $13.235. Analysts tracking the stock have a 12-month average target price of $20.91.
Its 50-day moving average was $3.3 and 200-day moving average was $4.61 The short ratio stood at 6.11 indicating a short percent outstanding of 0%.
Around 1132% of the company’s stock are held by insiders while 8119.1% are held by institutions.
Frequently Asked Questions About C4 Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.